Gilteritinib hemifumarate
Cat.No:IG4980 Solarbio
CAS:1254053-84-3
Molecular Formula:C29H44N8O3 0.5C4H4O4
Molecular Weight:610.75
Storage:Powder:2-8℃,2 years.
Purity:≥98%
Appearance:Off-white to yellow Solid
Qty:
Size:
{{cart_num}}
My Cart>
Small Molecule Compounds >
Inhibitors & Antagonists & Agonists >
Gilteritinib hemifumarateCAS:1254053-84-3
Molecular Formula:C29H44N8O3 0.5C4H4O4
Molecular Weight:610.75
Storage:Powder:2-8℃,2 years.
Purity:≥98%
Appearance:Off-white to yellow Solid
Qty:
Size:
CAS | 1254053-84-3 |
Name | Gilteritinib hemifumarate |
Molecular Formula | C29H44N8O3 0.5C4H4O4 |
Molecular Weight | 610.75 |
Solubility | Soluble in DMSO ≥0.3mg/mL |
Purity | ≥98% |
Appearance | Off-white to yellow Solid |
Storage | Powder:2-8℃,2 years. |
Target Point | FLT3;TAM Receptor(Axl) |
Passage | Angiogenesis; Protein Tyrosine Kinase/RTK |
Background | Gilteritinib hemifumarate is a potent ATP-competitive dual inhibitor of FLT3 / AXL. |
Biological Activity | Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.[1-2] |
IC50 | IC50: 0.29 nM (FLT3)[1]IC50: 0.35 nM (LTK), 0.73 nM (AXL), 1.2 nM (EML4-ALK), 230 nM (c-KIT)[2] |
Data Literature Source | [1]. ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML). 2014 ASCO Annual Meeting. [2]. Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35(5):556-565. |
Unit | Bottle |
Specification | 1mg |
Remark:These protocols are for reference only. Solarbio does not independently validate these methods.
Note:
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no experimental images.
Sorry, there is no more information.
Sorry, there is no more information.